EpiBiologics, a leader in tissue-selective extracellular protein degradation, today announced that the first patient has been dosed with EPI-326 in its global Phase 1 clinical study. EPI-326 is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results